Quercetin-4'-O-β-D-glucopyranoside (QODG) Inhibits Angiogenesis by Suppressing VEGFR2-mediated Signaling in Zebrafish and Endothelial Cells

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Feb 21

PMID 22348123

Citations 15

Authors

Chen Lin

Menghua Wu

Jianyong Dong

Affiliations

Soon will be listed here.

Abstract

Background: Angiogenesis plays an important role in many physiological and pathological processes. Identification of small molecules that block angiogenesis and are safe and affordable has been a challenge in drug development. Hypericum attenuatum Choisy is a Chinese herb medicine commonly used for treating hemorrhagic diseases. The present study investigates the anti-angiogenic effects of quercetin-4'-O-β-D-glucopyranoside (QODG), a flavonoid isolated from Hypericum attenuatum Choisy, in vivo and in vitro, and clarifies the underlying mechanism of the activity.

Methodology/principal Findings: Tg(fli1:EGFP) transgenic zebrafish embryos were treated with different concentrations of quercetin-4'-O-β-D-glucopyranoside (QODG) (20, 60, 180 µM) from 6 hours post fertilisation (hpf) to 72 hpf, and adult zebrafish were allowed to recover in different concentrations of QODG (20, 60, 180 µM) for 7 days post amputation (dpa) prior morphological observation and angiogenesis phenotypes assessment. Human umbilical vein endothelial cells (HUVECs) were treated with or without VEGF and different concentrations of QODG (5, 20, 60, 180 µM), then tested for cell viability, cell migration, tube formation and apoptosis. The role of VEGFR2-mediated signaling pathway in QODG-inhibited angiogenesis was evaluated using quantitative real-time PCR (qRT-PCR) and Western blotting.

Conclusion/significance: Quercetin-4'-O-β-D-glucopyranoside (QODG) was shown to inhibit angiogenesis in human umbilical vein endothelial cells (HUVECs) in vitro and zebrafish in vivo via suppressing VEGF-induced phosphorylation of VEGFR2. Our results further indicate that QODG inhibits angiogenesis via inhibition of VEGFR2-mediated signaling with the involvement of some key kinases such as c-Src, FAK, ERK, AKT, mTOR and S6K and induction of apoptosis. Together, this study reveals, for the first time, that QODG acts as a potent VEGFR2 kinase inhibitor, and exerts the anti-angiogenic activity at least in part through VEGFR2-mediated signaling pathway.

Citing Articles

Flavonoids with Anti-Angiogenesis Function in Cancer.

Wei Q, Zhang Y Molecules. 2024; 29(7).

PMID: 38611849 PMC: 11013936. DOI: 10.3390/molecules29071570.

Multi-omics analysis reveals promiscuous -glycosyltransferases involved in the diversity of flavonoid glycosides in (Apocynaceae).

Wang X, Wu L, Zhang W, Qiu S, Xu Z, Wan H Comput Struct Biotechnol J. 2024; 23:1106-1116.

PMID: 38495554 PMC: 10940802. DOI: 10.1016/j.csbj.2024.02.028.

Hypericum Genus as a Natural Source for Biologically Active Compounds.

Infante Caldeira G, Gouveia L, Serrano R, Silva O Plants (Basel). 2022; 11(19).

PMID: 36235373 PMC: 9573133. DOI: 10.3390/plants11192509.

Zebrafish as a Useful Model to Study Oxidative Stress-Linked Disorders: Focus on Flavonoids.

Abbate F, Maugeri A, Laura R, Levanti M, Navarra M, Cirmi S Antioxidants (Basel). 2021; 10(5).

PMID: 33922976 PMC: 8147052. DOI: 10.3390/antiox10050668.

Antiangiogenic Activity of Flavonoids: A Systematic Review and Meta-Analysis.

Khater M, Greco F, Osborn H Molecules. 2020; 25(20).

PMID: 33066630 PMC: 7594036. DOI: 10.3390/molecules25204712.

References

Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N, Shibuya M . Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc Natl Acad Sci U S A. 2005; 102(4):1076-81. PMC: 545830. DOI: 10.1073/pnas.0404984102. View

Ferrara N . VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002; 2(10):795-803. DOI: 10.1038/nrc909. View

Martinez-Poveda B, Quesada A, Medina M . Hyperforin, a bio-active compound of St. John's Wort, is a new inhibitor of angiogenesis targeting several key steps of the process. Int J Cancer. 2005; 117(5):775-80. DOI: 10.1002/ijc.21246. View

Rousseau S, Houle F, Huot J . Integrating the VEGF signals leading to actin-based motility in vascular endothelial cells. Trends Cardiovasc Med. 2001; 10(8):321-7. DOI: 10.1016/s1050-1738(01)00072-x. View

Serbedzija G, Flynn E, Willett C . Zebrafish angiogenesis: a new model for drug screening. Angiogenesis. 2003; 3(4):353-9. DOI: 10.1023/a:1026598300052. View

Li W, Tan D, Zhang Z, Liang J, Brown R . Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma. Oncol Rep. 2008; 20(4):713-9. View

Verheul H, Hoekman K, Eekman C, Folman C, Broxterman H, Pinedo H . Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res. 1998; 3(12 Pt 1):2187-90. View

Tufro A, Norwood V, Carey R, Gomez R . Vascular endothelial growth factor induces nephrogenesis and vasculogenesis. J Am Soc Nephrol. 1999; 10(10):2125-34. DOI: 10.1681/ASN.V10102125. View

Kamba T, McDonald D . Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007; 96(12):1788-95. PMC: 2359962. DOI: 10.1038/sj.bjc.6603813. View

10.

Foekens J, Peters H, Grebenchtchikov N, Look M, Meijer-van Gelder M, Geurts-Moespot A . High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 2001; 61(14):5407-14. View

11.

Schlessinger J . New roles for Src kinases in control of cell survival and angiogenesis. Cell. 2000; 100(3):293-6. DOI: 10.1016/s0092-8674(00)80664-9. View

12.

Dumont D, Fong G, Puri M, Gradwohl G, Alitalo K, Breitman M . Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn. 1995; 203(1):80-92. DOI: 10.1002/aja.1002030109. View

13.

Roberts D, Kearney J, Johnson J, Rosenberg M, Kumar R, Bautch V . The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. Am J Pathol. 2004; 164(5):1531-5. PMC: 1615669. DOI: 10.1016/S0002-9440(10)63711-X. View

14.

Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M . A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene. 1995; 10(1):135-47. View

15.

Chintalgattu V, Nair D, Katwa L . Cardiac myofibroblasts: a novel source of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR. J Mol Cell Cardiol. 2003; 35(3):277-86. DOI: 10.1016/s0022-2828(03)00006-3. View

16.

Ren W, Qiao Z, Wang H, Zhu L, Zhang L . Flavonoids: promising anticancer agents. Med Res Rev. 2003; 23(4):519-34. DOI: 10.1002/med.10033. View

17.

Ito N, Wernstedt C, Engstrom U, Claesson-Welsh L . Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules. J Biol Chem. 1998; 273(36):23410-8. DOI: 10.1074/jbc.273.36.23410. View

18.

Baek J, Jang J, Kang C, Chung H, Kim N, Kim K . Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene. 2000; 19(40):4621-31. DOI: 10.1038/sj.onc.1203814. View

19.

Compagni A, Christofori G . Recent advances in research on multistage tumorigenesis. Br J Cancer. 2000; 83(1):1-5. PMC: 2374546. DOI: 10.1054/bjoc.2000.1309. View

20.

Huang C, Wang T, Lin B, Wang Y, Johnson S, Yu J . Collagen IX is required for the integrity of collagen II fibrils and the regulation of vascular plexus formation in zebrafish caudal fins. Dev Biol. 2009; 332(2):360-70. PMC: 3690564. DOI: 10.1016/j.ydbio.2009.06.003. View